Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status Meeting Abstract
| Authors: | Gordon, M. S.; Matei, D.; Aghajanian, C.; Matulonis, U. A.; Brewer, M. A.; Fleming, G. F.; Hainsworth, J. D.; Garcia, A. A.; Pegram, M.; Karlan, B. Y. |
| Abstract Title: | Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status |
| Meeting Title: | 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 23 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2005 May 13-17 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2005-06-01 |
| Start Page: | 467S |
| Language: | English |
| ACCESSION: | WOS:000230326603093 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2005.23.16_suppl.5051 |
| Notes: | --- - Meeting Abstract: 5051 - 41st Annual Meeting of the American-Society-of-Clinical-Oncology - MAY 13-17, 2005 - Orlando, FL - S - Part 1 - "Source: Wos" |
